Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TVTX 
Travere Therapeutics Inc (TVTX)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: TVTX (5-star) is a STRONG-BUY. BUY since 47 days. Simulated Profits (55.38%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $35.93
1 Year Target Price $35.93
| 11 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 125.6% | Avg. Invested days 37 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.33B USD | Price to earnings Ratio - | 1Y Target Price 35.93 |
Price to earnings Ratio - | 1Y Target Price 35.93 | ||
Volume (30-day avg) 15 | Beta 0.84 | 52 Weeks Range 12.91 - 28.69 | Updated Date 10/15/2025 |
52 Weeks Range 12.91 - 28.69 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -50.64% | Operating Margin (TTM) -11.05% |
Management Effectiveness
Return on Assets (TTM) -19.28% | Return on Equity (TTM) -705.73% |
Valuation
Trailing PE - | Forward PE 19.76 | Enterprise Value 2238974660 | Price to Sales(TTM) 6.98 |
Enterprise Value 2238974660 | Price to Sales(TTM) 6.98 | ||
Enterprise Value to Revenue 6.71 | Enterprise Value to EBITDA -5.67 | Shares Outstanding 89138673 | Shares Floating 79287067 |
Shares Outstanding 89138673 | Shares Floating 79287067 | ||
Percent Insiders 0.75 | Percent Institutions 116.31 |
Upturn AI SWOT
Travere Therapeutics Inc
Company Overview
History and Background
Travere Therapeutics, Inc. (formerly known as Silver Creek Pharmaceuticals) was founded in 2011. It is a biopharmaceutical company focused on the identification, development, and commercialization of innovative therapies for rare diseases.
Core Business Areas
- Kidney Disease: Focuses on developing and commercializing therapies for rare kidney disorders. Key products target conditions like FSGS and IgA nephropathy.
Leadership and Structure
Eric Dube is the current CEO. The company has a typical corporate structure with departments like R&D, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Filspari (sparcentan): Filspari is approved for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of rapid disease progression. Competing products are SGLT2 inhibitors (e.g. Jardiance, Farxiga) although they have different mechanisms of action, and traditional supportive care like ACE inhibitors and ARBs. Market share is still evolving as Filspari is a relatively new entrant.
Market Dynamics
Industry Overview
The biopharmaceutical industry focusing on rare diseases is growing, driven by unmet medical needs and regulatory incentives. It's characterized by high development costs and significant market exclusivity periods.
Positioning
Travere Therapeutics is positioned as a player in the rare kidney disease space, aiming to address unmet needs with targeted therapies. Their competitive advantage lies in their focus and specialized knowledge.
Total Addressable Market (TAM)
The TAM for rare kidney diseases is estimated to be in the billions of dollars. Travere's position is that of a mid-sized player trying to capture significant market share within specific rare disease segments.
Upturn SWOT Analysis
Strengths
- Specialized focus on rare kidney diseases
- FDA-approved product (Filspari)
- Experienced management team
- Strong pipeline of potential therapies
Weaknesses
- Reliance on a limited number of products
- High R&D costs
- Small market size for rare diseases can limit revenue potential
- Dependence on successful clinical trials and regulatory approvals
Opportunities
- Expanding indications for existing products
- Acquiring or in-licensing new therapies
- Entering new geographic markets
- Advancements in diagnostic technologies for early disease detection
Threats
- Competition from larger pharmaceutical companies
- Generic entry of existing products
- Unfavorable regulatory changes
- Failure of clinical trials
- Pricing pressures from payers
Competitors and Market Share
Key Competitors
- GSK
- LLY
- NVO
Competitive Landscape
Travere faces competition from larger pharmaceutical companies with greater resources. Travere's competitive advantage lies in its specialized focus and knowledge of rare kidney diseases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on revenue from Filspari. Growth is dependent on successful product launches and pipeline development.
Future Projections: Future projections depend on analyst estimates and company guidance. Look for information from reputable financial news outlets.
Recent Initiatives: Focus on expanding Filspari's market reach and developing new therapies for rare kidney diseases.
Summary
Travere Therapeutics is a biopharmaceutical company focused on rare kidney diseases, with Filspari as its key product. While its specialized focus provides an advantage, it faces challenges related to competition and R&D costs. The company needs to continue its focus on strategic deals and expanding indications to acheive long term growth. The company is also in a net debt position making capital allocation decisions important.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company 10K/10Q filings
- Analyst reports
- Third-party market research reports
- Company website
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Market share is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Travere Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2012-11-08 | President, CEO & Director Dr. Eric M. Dube Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 385 | Website https://www.travere.com |
Full time employees 385 | Website https://www.travere.com | ||
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.